Secobarbital Sodium-Yimin Pharm

Secobarbital Sodium-Yimin Pharm Uses, Dosage, Side Effects, Food Interaction and all others data.

Secobarbital Sodium-Yimin Pharm (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom.

Secobarbital Sodium-Yimin Pharm, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.

Secobarbital Sodium-Yimin Pharm
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Secobarbital Sodium-Yimin Pharm
Availability	Discontinued
Generic	Secobarbital
Secobarbital Other Names	Quinalbarbitone, Secobarbital, Secobarbitalum, Secobarbitone
Related Drugs	trazodone, hydroxyzine, amitriptyline, lorazepam, diazepam, melatonin, zolpidem, promethazine, diphenhydramine, fentanyl
Type
Formula	C₁₂H₁₈N₂O₃
Weight	Average: 238.2829 Monoisotopic: 238.131742452
Groups	Approved, Vet approved
Therapeutic Class
Manufacturer
Available Country	China
Last Updated:	September 19, 2023 at 7:00 am

Uses

Secobarbital Sodium-Yimin Pharm is a barbiturate used for the short-term treatment of insomnia.

For the Short-term treatment of intractable insomnia for patients habituated to barbiturates

Secobarbital Sodium-Yimin Pharm is also used to associated treatment for these conditions: Insomnia, Preanesthetic medication therapy

How Secobarbital Sodium-Yimin Pharm works

Secobarbital Sodium-Yimin Pharm binds at a distinct binding site associated with a Cl^- ionopore at the GABA_A receptor, increasing the duration of time for which the Cl^- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

Toxicity

Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.

Food Interaction

Avoid alcohol. Taking with alcohol may cause additive CNS depression.
Take on an empty stomach. This may increase the rate of absorption.

Secobarbital Sodium-Yimin Pharm Alcohol interaction

[Major] GENERALLY AVOID:

Concurrent acute use of barbiturates and ethanol may result in additive CNS effects,

including impaired coordination, sedation, and death.

Tolerance of these agents may occur with chronic use.

The mechanism is related to inhibition of microsomal enzymes acutely and induction of hepatic microsomal enzymes chronically.

The combination of ethanol and barbiturates should be avoided.

Secobarbital Sodium-Yimin Pharm Hypertension interaction

[Major] The intravenous administration of barbiturates may produce severe cardiovascular reactions such as bradycardia, hypertension, or vasodilation with fall in blood pressure, particularly during rapid infusion.

Parenteral therapy with barbiturates should be administered cautiously in patients with hypertension, hypotension, or cardiac disease.

The intravenous administration of barbiturates should be reserved for emergency treatment of acute seizures or for anesthesia.

Secobarbital Sodium-Yimin Pharm Drug Interaction

Major: acetaminophen / oxycodoneModerate: aripiprazole, zolpidem, diphenhydramine, olmesartan, methohexital, clonazepam, mirtazapine, ramelteon, levothyroxine, diazepam, alprazolam, cetirizineUnknown: aspirin, amphetamine / dextroamphetamine, mannitol, amoxicillin / clavulanate, flax, esomeprazole, lisdexamfetamine

Secobarbital Sodium-Yimin Pharm Disease Interaction

Major: acute alcohol intoxication, drug dependence, liver disease, porphyria, rash, respiratory depression, cardiovascular, prolonged hypotensionModerate: adrenal insufficiency, depression, hematologic toxicity, osteomalacia, paradoxical reactions

Elimination Route

Barbiturates are metabolized primarily by the hepatic microsomal enzyme system, and the metabolic products are excreted in the urine and, less commonly, in the feces.